FDA Approves Lymphoseek to Help Locate Lymph Nodes

For use among people with certain cancers

WEDNESDAY, March 13 (HealthDay News) -- The injected imaging drug Lymphoseek (technetium Tc 99m tilmanocept) has been approved by the U.S. Food and Drug Administration to help surgeons locate the lymph nodes among people with breast cancer or melanoma who are undergoing surgery to remove tumor-draining lymph nodes.

Lymphoseek is an imaging drug that helps locate the lymph nodes, but it is not a cancer imaging drug, the agency stressed. It's the first lymph-node mapping drug to be approved by the FDA in 30 years.

The drug's safety and effectiveness were established in clinical trials involving 332 people with melanoma or breast cancer. The most common adverse reactions reported were pain and/or irritation at the injection site.

Lymphoseek is marketed by Navidea Biopharmaceuticals, based in Dublin, Ohio.

More Information

Health News Copyright © 2013 HealthDay. All rights reserved.

Powered by

Featured Jobs

Learning Centers

Find in-depth content on major issues provided by leading companies in partnership with NursingCenter.com

BD Safety Beyond Needlestick Prevention Learning Center

Sponsored by BD Medical




Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

CESaver
Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member